LTRN News and Press, Lantern Pharma Inc. From 03/18/24

Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-184 in the second half of 2024; with additional next-generation drug development programs approaching IND studies. Dosed initial patients in both Phase 1 clinical trials for...

Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...

2024-03-17 17:35:21 ET Major earnings expected after the bell on Monday include: StoneCo Ltd. ( STNE ) JOYY ( YY ) Bit Digital ( BTBT ) Xiaomi Corporation ( OTCPK:XIACF ) DLocal Limited ( DLO ) Read the full article on Seeking Alpha Fo...

LP-284 is in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and other solid tumors. LP-284 is the second of Lantern’s synthetic-lethal fra...

2024-03-11 12:49:34 ET Gainers: Kidpik Corp ( PIK ) +118% . TC BioPharm ( TCBP ) +94% . L.S. Starrett Co. ( SCX ) +59% . Kingsoft Cloud Holdings Ltd ( KC ) +33% . Energem Corp ( ENCP ) +31% . NextNav ( NN ) +28% . ...

Webcast to be held Monday, March 18th, 4:30 p.m. ET, register for the webcast here , or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN ), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its prop...

Lantern Pharma will present virtually on Thursday, March 7 th at 2 pm Eastern. Lantern’s CEO & President, Mr. Panna Sharma will be interviewed in the form of a fireside chat by HCW’s Healthcare & Life Sciences Analyst and Director of Equity Research Insti...

The rapid growth of Lantern Pharma’s AI platform could lead to accelerated development of better treatments, greater precision in clinical development, and improved combination regimens with the potential for longer and more durable patient responses. Lantern's RADR ® plat...

Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC. The cryptophycin ADC has shown picomolar potency in a wide range of solid tumors tested in preclinical de...

Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D. has joined Starl...